Australia's most trusted
source of pharma news
Posted 16 November 2023 AM
A staggering 34 applications recommended by the PBAC over the past three years have either stalled or been dropped by companies, a Pharma in Focus analysis shows.
The analysis looked at drugs recommended from the July 2020 meeting to the same meeting this year with 21 applications considered 'inactive' and 13 applications 'ceased'.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.